X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CYAD-01 is an autologous CAR T-cell candidate based on the fusion of the NKG2D receptor with CD3ζ. Co-stimulation is ensured by endogenous DAP10. It is being investigated for hematological malignancies, AML, MDS), or multiple myeloma (MM)] and solid tumors.
Lead Product(s): CYAD-01
Therapeutic Area: Oncology Product Name: CYAD-01
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
CYAD-101 is an investigational, non-gene edited allogeneic CAR T engineered to co-express chimeric antigen receptor based on NKG2D, that binds to eight stress-induced ligands expressed by a broad range of tumor cells and the novel inhibitory peptide TIM.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Company announced clinical hold on CYAD-101-002 Phase 1b trial for CYAD-101, TCR Inhibitory Molecule based allogeneic NKG2D CAR T cell investigational therapy for treatment of advanced mCRC, due to insufficient information to assess risk to study subjects.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
The trial is evaluating TCR Inhibitory Molecule-based allogeneic NKG2D CAR T cell investigational therapy CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with refractory metastatic colorectal cancer.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
The Company intends to use net proceeds from the private placement to fund research and development expenses, including the clinical development of its allogeneic CAR T candidates CYAD-101 and CYAD-211, to advance the current pipeline of preclinical CAR T candidates.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fortress Investment Group
Deal Size: $32.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 03, 2021
Details:
The recommended dose of 1×109 CYAD-101 cells per infusion will be further evaluated in the expansion cohort of the alloSHRINK trial concurrently with FOLFIRI chemotherapy.
Lead Product(s): CYAD-101,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: CYAD-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
The presentations will focus on the company’s anti-BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates CYAD-01 and CYAD-02.
Lead Product(s): CYAD-211,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: CYAD-211
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Two patients achieved a confirmed partial response and nine patients achieved stable disease, leading to a disease control rate of 73% following tretment with CYAD-101.
Lead Product(s): CYAD-101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Data from this study will provide insights into the pharmacokinetic profile of the four formulations and provide guidance on final formulation selection and dosing for future clinical trials.
Lead Product(s): CYAD-02
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
